 Cytochrome P-450 CYP2C19
"Cytochrome P-450 CYP2C19" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P-450 enzyme subtype that oxidizes several important groups of drugs including many PROTON PUMP INHIBITORS and ANTICONVULSANTS.
| Descriptor ID |
D065731
|
| MeSH Number(s) |
D08.244.453.491.500.700 D08.811.682.690.708.170.450.500.700 D12.776.422.220.453.491.500.700
|
| Concept/Terms |
Cytochrome P-450 CYP2C19- Cytochrome P-450 CYP2C19
- CYP2C19, Cytochrome P-450
- Cytochrome P 450 CYP2C19
- P-450 CYP2C19, Cytochrome
- CYPIIC19
- S-Mephenytoin 4'-Hydroxylase
- 4'-Hydroxylase, S-Mephenytoin
- S Mephenytoin 4' Hydroxylase
- CYP2C19
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2C19".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2C19".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2C19" by people in this website by year, and whether "Cytochrome P-450 CYP2C19" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 | | 2015 | 1 | 0 | 1 | | 2019 | 0 | 1 | 1 | | 2020 | 0 | 2 | 2 | | 2021 | 0 | 1 | 1 | | 2022 | 0 | 2 | 2 | | 2024 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2C19" by people in Profiles.
-
Aquilante CL, Trinkley KE, Lee YM, Crooks KR, Hearst EC, Heckman SM, Hess KW, Kudron EL, Martin JL, Swartz CT, Kao DP. Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program. Am J Health Syst Pharm. 2024 Jun 11; 81(12):555-562.
-
Brown T, Gonzales N. Optimizing Choice of Dual Antiplatelet Therapy in CYP2C19 Loss-of-Function Carriers. Neurology. 2023 01 31; 100(5):223-224.
-
Anderson HD, Thant TM, Kao DP, Crooks KR, Mendola ND, Aquilante CL. Pharmacogenetic testing among patients with depression in a US managed care population. Clin Transl Sci. 2022 07; 15(7):1644-1653.
-
Tuteja S, Salloum RG, Elchynski AL, Smith DM, Rowe E, Blake KV, Limdi NA, Aquilante CL, Bates J, Beitelshees AL, Cipriani A, Duong BQ, Empey PE, Formea CM, Hicks JK, Mroz P, Oslin D, Pasternak AL, Petry N, Ramsey LB, Schlichte A, Swain SM, Ward KM, Wiisanen K, Skaar TC, Van Driest SL, Cavallari LH, Bishop JR. Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy. Clin Transl Sci. 2022 02; 15(2):371-383.
-
Ramsey LB, Ong HH, Schildcrout JS, Shi Y, Tang LA, Hicks JK, El Rouby N, Cavallari LH, Tuteja S, Aquilante CL, Beitelshees AL, Lemkin DL, Blake KV, Williams H, Cimino JJ, Davis BH, Limdi NA, Empey PE, Horvat CM, Kao DP, Lipori GP, Rosenman MB, Skaar TC, Teal E, Winterstein AG, Owusu Obeng A, Salyakina D, Gupta A, Gruber J, McCafferty-Fernandez J, Bishop JR, Rivers Z, Benner A, Tamraz B, Long-Boyle J, Peterson JF, Van Driest SL. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. JAMA Netw Open. 2020 12 01; 3(12):e2029411.
-
Gutierrez JA, Heizer GM, Jones WS, Rockhold FW, Mahaffey KW, Fowkes FGR, Berger JS, Baumgartner I, Held P, Katona BG, Norgren L, Blomster JI, Hiatt WR, Patel MR. CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. Am Heart J. 2020 11; 229:118-120.
-
Aquilante CL, Kao DP, Trinkley KE, Lin CT, Crooks KR, Hearst EC, Hess SJ, Kudron EL, Lee YM, Liko I, Lowery J, Mathias RA, Monte AA, Rafaels N, Rioth MJ, Roberts ER, Taylor MR, Williamson C, Barnes KC. Clinical implementation of pharmacogenomics via a health system-wide research biobank: the University of Colorado experience. Pharmacogenomics. 2020 04; 21(6):375-386.
-
Lazorwitz A, Aquilante CL, Sheeder J, Teal S. Letter to the Editor in Response to "Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally". Adv Ther. 2020 02; 37(2):963-964.
-
Hillman L, Yadlapati R, Thuluvath AJ, Berendsen MA, Pandolfino JE. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Dis Esophagus. 2017 Sep 01; 30(9):1-15.
-
Flaten HK, Kim HS, Campbell J, Hamilton L, Monte AA. CYP2C19 drug-drug and drug-gene interactions in ED patients. Am J Emerg Med. 2016 Feb; 34(2):245-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|